Radiopharmaceuticals are rapidly gaining attention across the biopharma industry, combining targeted delivery with therapeutic radioisotopes to address some of the most challenging cancers. At BiopharmIQ, we have mapped 119 therapeutic radiopharma companies worldwide that are active in this space, from clinical-stage innovators to established commercial players. To give you a snapshot of this growing field, we’ve highlighted 10 companies that exemplify the progress being made through clinical advancements, financing milestones, technology innovation, and strategic positioning. Do you have them on your radar?

💰 ITM Isotope Technologies Munich (Germany)

Focus: Targeted radiopharmaceutical therapies using Lutetium-177. ITM has built a global reputation for precision radiopharma. Its lead candidate, ITM-11 (177Lu-edotreotide), reported positive Phase 3 COMPETE results in neuroendocrine tumors, showing significantly improved progression-free survival. Backed by a recent $262.5M financing, ITM is preparing for a U.S. NDA filing in 2025, making it one of the most advanced late-stage players in the space.

☢️ Clarity Pharmaceuticals (Australia)

Focus: Copper-64 and Copper-67-based theranostic. Clarity is pioneering the use of copper isotopes as an alternative to Lutetium. Its Cu-67 bisPSMA program recently received FDA Fast Track designation and entered Phase II expansion, while a Cu-64 PET trial is ongoing. By leveraging the unique pharmacokinetics of copper, Clarity is driving forward a new isotope class that could reshape theranostic strategies.

🔬 Actinium Pharmaceuticals (United States)

Focus: Actinium-225 antibody-radionuclide conjugates via its Antibody Warhead Enabling (AWE™) platform.

Actinium specializes in developing Ac-225 conjugates for hematologic cancers. Its lead candidate, Actimab-A, is being evaluated in AML, and the AWE™ platform is designed to generate next-generation constructs for broader oncology applications. With multiple trials underway, Actinium is one of the few companies with deep expertise in antibody-linked alpha therapies.

🔬 Alpha Fusion (Japan)

Focus: Targeted Alpha Therapy (TAT) with Astatine-211 (At-211).

Alpha Fusion is advancing a novel pipeline based on the alpha-emitter At-211, which combines short half-life, high precision, and rapid clearance from the body. Its clinical candidates include αf-001 for refractory thyroid cancer and αf-002 for prostate cancer. By applying At-211’s unique properties, Alpha Fusion aims to deliver repeatable, precise alpha therapies for patients with limited treatment options.

💰 ARTBIO (United States)

Focus: Pb-212 alpha radiopharmaceuticals supported by its proprietary AlphaDirect™ platform.

ARTBIO is pairing innovation in isotope supply with a growing clinical pipeline. Its lead program, AB001 (212Pb-NG001), is advancing in solid tumors, while its AlphaDirect™ technology enables reliable production of Pb-212. A $132M Series B in 2025 underscored investor confidence in both its therapeutic programs and isotope infrastructure.

💰 Nuclidium (Switzerland)

Focus: Copper-based theranostics via its CuTrace™ platform.

Nuclidium is building a pipeline around copper isotopes Cu-64 and Cu-67, designed to deliver imaging and therapeutic solutions from the same chemical backbone. The company raised €84M ($98M) Series B in 2025 to scale its platform and accelerate clinical programs. Nuclidium is emerging as a leader in copper radiopharma innovation.

💡 Precirix (Belgium)

Focus: Antibody-based radiopharmaceuticals with camelid antibody constructs.

Precirix is advancing a Phase 2 HER2-targeted radiopharma program (CAM-H2) using single-domain antibodies. Its platform allows for highly selective delivery of therapeutic isotopes to tumors, opening new possibilities for antibody-radiopharmaceutical conjugates. Precirix is one of the few companies combining antibody engineering with radiopharma precision.

☢️ Curium Pharma (France)

Focus: Large-scale nuclear medicine and theranostic radiopharmaceuticals.

Curium is one of the largest independent radiopharma players, with global reach across diagnostics and therapeutics. The company is currently advancing a Phase 3 program with 177Lu-PSMA-I&T while investing heavily in theranostic pairings. With its scale and infrastructure, Curium is a key driver of radiopharma commercialization worldwide.

💡 Fuzionaire Theranostics (United States)

Focus: Radiopharmaceuticals built on the HetSiFA® chelation platform. Spun out from Nobel laureate Robert Grubbs’ lab at Caltech, Fuzionaire is developing next-generation chelation chemistry to improve isotope stability, especially for alpha emitters like Ac-225. Its HetSiFA® technology enables more effective and reliable binding of isotopes to targeting ligands, supporting a wide range of oncology applications.

🔬 Radionetics Oncology (United States)

Focus: Small-molecule radiopharmaceuticals for oncology.

Radionetics is advancing a pipeline of 68Ga/177Lu agents, with a Phase 1 trial initiated in August 2025. By combining small-molecule drug discovery expertise with radioligand therapy, Radionetics represents a new generation of West Coast biotechs applying precision radiochemistry to solid tumors.

Closing Thoughts

These 10 companies showcase the diversity of radiopharmaceutical innovation, from late-stage clinical programs and FDA designations to novel isotopes and platform technologies. Whether through Lutetium, Copper, Astatine, Actinium, or Lead isotopes, radiopharma is proving to be a transformative modality in oncology.

👉 Want to explore the broader landscape? Explore our free list of 119 radiopharma companies mapped by BiopharmIQ, covering innovators, scale-ups, and global leaders.

How can you get the most out of this list?

Start by creating a free BiopharmIQ account or request a free trial to explore our platform in detail.

You’re also welcome to book a demo with our team, who can walk you through the platform and show you how to tailor insights to your specific business development needs.

Article History:

9/8/25 MD, DG

Not legal, investing, or tax advice.